Chloroquine

Generic Name
Chloroquine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H26ClN3
CAS Number
54-05-7
Unique Ingredient Identifier
886U3H6UFF
Background

Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other c...

Indication

Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
...

Associated Conditions
Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
Associated Therapies
-
Clinical Trials
Related News

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

First Posted Date
2016-05-16
Last Posted Date
2019-12-27
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
28
Registration Number
NCT02773979
Locations
🇺🇸

Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States

Evaluating the Role of Chloroquine for Malaria Elimination

Phase 2
Completed
Conditions
Malaria
Interventions
Drug: Placebo
Drug: Chloroquine
First Posted Date
2016-03-04
Last Posted Date
2018-02-07
Lead Sponsor
Centro de Investigacao em Saude de Manhica
Target Recruit Count
75
Registration Number
NCT02698748
Locations
🇲🇿

Centro de Investigaçao em Saude de Manhiça, Manhiça, Maputo, Mozambique

Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection

Phase 2
Completed
Conditions
Malaria, Vivax
Interventions
Drug: Chloroquine
Drug: Primaquine
First Posted Date
2016-02-25
Last Posted Date
2016-02-25
Lead Sponsor
Oswaldo Cruz Foundation
Target Recruit Count
204
Registration Number
NCT02691910
Locations
🇧🇷

Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

🇧🇷

Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil

Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam

Phase 4
Conditions
Plasmodium Vivax
Interventions
Drug: Chloroquine
First Posted Date
2015-11-20
Last Posted Date
2016-03-23
Lead Sponsor
National Institute of Malariology, Parasitology and Entomology, Vietnam
Target Recruit Count
100
Registration Number
NCT02610686
Locations
🇻🇳

Chu R Cam, Pleiku, Gia Lai, Vietnam

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.

First Posted Date
2015-09-30
Last Posted Date
2021-05-13
Lead Sponsor
State University of New York - Upstate Medical University
Target Recruit Count
103
Registration Number
NCT02564471
Locations
🇺🇸

State University of New York, Upstate Medical University (SUNY-UMU), Syracuse, New York, United States

A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria

Phase 2
Completed
Conditions
Malaria, Vivax
Interventions
Drug: Tafenoquine
Drug: Chloroquine
First Posted Date
2015-09-30
Last Posted Date
2020-11-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
60
Registration Number
NCT02563496
Locations
🇻🇳

GSK Investigational Site, Ho Chi Minh, Vietnam

The Addition of Chloroquine to Chemoradiation for Glioblastoma,

Phase 2
Withdrawn
Conditions
Astrocytoma, Grade IV
Glioblastoma
Interventions
Drug: Chloroquine
First Posted Date
2015-05-04
Last Posted Date
2023-11-18
Lead Sponsor
Maastricht Radiation Oncology
Registration Number
NCT02432417

Effectiveness of Malaria Treatment in Mexico

Phase 4
Completed
Conditions
Malaria
Interventions
Drug: Chloroquine phosphate
Drug: primaquine
First Posted Date
2015-03-20
Last Posted Date
2015-03-20
Lead Sponsor
LILIA GONZALEZ CERON
Target Recruit Count
153
Registration Number
NCT02394197

A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh

First Posted Date
2015-03-17
Last Posted Date
2024-03-13
Lead Sponsor
Menzies School of Health Research
Target Recruit Count
181
Registration Number
NCT02389374

The Addition of Chloroquine to Chemoradiation for Glioblastoma

First Posted Date
2015-03-04
Last Posted Date
2020-01-23
Lead Sponsor
Maastricht Radiation Oncology
Target Recruit Count
13
Registration Number
NCT02378532
Locations
🇳🇱

Maastricht Radiation Oncology, Maastricht, Netherlands

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy